Insilico Medicine ("Insilico"), a objective stage, end-to-end artificial quality (AI)-driven cause find company, held the motorboat ceremonial for Life Star – a 6th procreation Intelligent Robotics Drug Discovery Laboratory – successful Suzhou BioBAY Industrial Park connected Dec. 29. The afloat automated AI-powered robotics laboratory performs people discovery, compound screening, precision medicine development, and translational research. The laboratory volition let Insilico to further accelerate its end-to-end cause find and optimize the occurrence complaint of its cause improvement arsenic it moves its caller therapeutics done objective trials.
High-throughput screening, automatic modules, and instrumentality learning information procreation are not caller successful the biomedical sector. To date, 5th procreation robotics laboratories person realized afloat automation with nary quality bias oregon influence, connected aggregate processes, and generated high-quality information that tin beryllium utilized for instrumentality learning. Insilico Medicine's laboratory takes this process 1 measurement further to incorporated AI successful decision-making and profoundly integrate AI with automation, robotics, and biologic capabilities to alteration a caller procreation of intelligent robotic labs.
We anticipation to usher successful a caller epoch of biology labs. Insilico's robotics laboratory has an AI brain, an automated instrumentality body, and the limbs of assorted analyzable robots. The AI encephalon has been trained and verified done Insilico projects and has learned from years of acquisition collaborating with planetary pharmaceutical companies. It tin transportation retired systematic learning based connected the accusation provided, and assistance successful the decision-making of people find and identification. In the Intelligent Robotics Lab, the AI encephalon volition suggest imaginable targets and plan automated experiments and workflows based connected experimental results."
Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine
The Intelligent Robotics Lab forms a closed loop by combining Pharma.AI (Insilico Medicine's end-to-end AI level for people discovery, caller cause design, and objective proceedings prediction) with afloat automated biologic experimentation functional modules.
Specifically, aft the Pharma.AI people find level PandaOmics predicts caller targets for circumstantial diseases, the robotics laboratory volition behaviour early-stage cause find experiments similar people validation, high-throughput deed compound screening, hit-to-lead optimization, lead-to-preclinical campaigner (PCC) confirmation, and translational research. These biologic experiments that are traditionally conducted by humans volition beryllium achieved done six afloat automated modules including illustration absorption and prime control, compound management, automated compartment culture, high-throughput screening, high-content compartment imaging, and next-generation sequencing. All the high-quality information generated by the robotics laboratory volition complement and grow Insilico's existing information resources to bid and optimize the AI platform, further strengthening Insilico's biologic information factory.
Feng Ren, PhD, Chief Scientific Officer and co-CEO of Insilico Medicine, said, "Target recognition is the root of caller cause development. One of the large challenges presently faced by the biomedical manufacture is uncovering the close target. Now, Insilico Medicine proposes a broad solution done the Intelligent Robotics Lab. First, the laboratory helps to place and verify imaginable targets efficiently. It past evaluates and analyzes the enactment and druggability of the compounds designed. In addition, it helps observe biomarkers and behaviour studies connected the mechanics of enactment during preclinical and translational research. The Robotics Lab has begun moving connected Insilico projects and we look guardant to providing this instrumentality to beforehand the probe of our world and concern partners."
Founded successful 2014, Insilico Medicine is 1 of the archetypal players successful AI-driven cause discovery. It has built a almighty and businesslike end-to-end AI platform, Pharma.AI, to amended the speed, cost, and ratio of cause discovery. Since 2021, Insilico has precocious 9 preclinical candidates, including cause candidates with caller targets and structures discovered by AI, and cause candidates with desirable properties designed by AI aiming astatine known targets. Projects are wide dispersed crossed aggregate illness areas including fibrosis, immuno-oncology, inflammation, and COVID-19.
English (US)